Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Tan and colleagues discuss recent advances in spatial omics and computational models that inform the classification and clinical relevance of cellular neighborhoods in cancer.
Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.
Neri and colleagues discuss the development of drug conjugates for cancer therapy, focusing on current and future opportunities to improve tumor-targeting efficacy with small molecule–drug conjugates and combination therapies.
Hata and colleagues discuss the complexity and clinical importance of cancer persister cells, as well as existing methods for studying and eliminating them, expanding on challenges and opportunities in this area of research.
De Palma and Hanahan outline advances in understanding tumor angiogenesis and discuss the therapeutic opportunities of targeting tumor vascularization.
Barker and colleagues discuss the interplay between circadian rhythm, the tumor microenvironment and stem cells and how these are linked to metastasis as well as how these interactions could be clinically relevant.
Green and colleagues discuss modes of cell death in cancer and focus on ‘near-death experiences’, whereby tumor cells engage the regulated cell death machinery yet survive, with far-reaching consequences for tumor survival, growth and therapy.
Rebbeck, Huang and colleagues discuss recent insights into health inequities related to clinical next-generation sequencing for precision oncology, the contributing factors as well as recommendations for resolution looking ahead.
Wells and colleagues discuss emerging insights into bystander T cells, including analytical methods, the role of bystander T cell subtypes in tumor immunology and the potential ways that these cells can be leveraged to improve cancer immunotherapy.
Beltran and colleagues discuss the challenges in treating metastatic prostate cancer and strategies to accelerate precision oncology and improve therapy and clinical decisions in this setting.
Aguirre-Ghiso and colleagues discuss the current status of the cancer dormancy field, including challenges and opportunities for monitoring and targeting dormant cancer.
Bozic and Wu discuss how quantitative mathematical models elucidate the various stages of tumor evolution, from premalignancy to malignant progression, and the response to therapy.
